New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2014
10:38 EDTENDP, BDSIEndo Health trial results more meaningful to partner, says Cantor
Cantor views the positive top-line results from the trial of BEMA buprenorphine reported by Endo Health (ENDP) as more meaningful to its partner, BioDelivery Sciences (BDSI), than to Endo. Cantor see the product opportunity for this drug to be modest and maintains its Sell rating and $43 price target on Endo Health.
News For ENDP;BDSI From The Last 14 Days
Check below for free stories on ENDP;BDSI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 25, 2014
09:26 EDTENDPEndo puts AMS medical-device unit up for sale, WSJ says
Subscribe for More Information
August 22, 2014
09:38 EDTBDSIBioDelivery Sciences sales may jump on DEA move, says Summer Street
Subscribe for More Information
August 19, 2014
07:34 EDTBDSIBioDelivery Sciences management to meet with William Blair
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use